Skip to main content
. Author manuscript; available in PMC: 2014 Oct 15.
Published in final edited form as: Cancer Res. 2013 Oct 4;73(20):10.1158/0008-5472.CAN-13-1558-T. doi: 10.1158/0008-5472.CAN-13-1558-T

Figure 7. In vivo anti-IL6 treatment reverses PanIN lesions.

Figure 7

(A) Experimental design, n=3. (B) Pathological analysis. Data represent mean ± SEM, n=3. (C, D) H&E staining of KPCY mice pancreata treated with isotype control (C) or anti-IL6 antibody (D) 1 week following the beginning of treatment. Scale bar 100μm. (E) Working model indicating the requirement of IL6 during the maintenance and progression of pancreatic cancer in mice.